Follow
Ameet Sarpatwari
Ameet Sarpatwari
Assistant Professor of Medicine at Harvard Medical School
Verified email at bwh.harvard.edu - Homepage
Title
Cited by
Cited by
Year
The high cost of prescription drugs in the United States: origins and prospects for reform
AS Kesselheim, J Avorn, A Sarpatwari
Jama 316 (8), 858-871, 2016
6442016
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review
R Stasi, A Sarpatwari, JB Segal, J Osborn, ML Evangelista, N Cooper, ...
Blood, The Journal of the American Society of Hematology 113 (6), 1231-1240, 2009
4582009
Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database
A Sarpatwari, D Bennett, JW Logie, A Shukla, KJ Beach, AC Newland, ...
haematologica 95 (7), 1167, 2010
2502010
Practical, legal, and ethical issues in expanded access to investigational drugs
JJ Darrow, A Sarpatwari, J Avorn, AS Kesselheim
New England Journal of Medicine 372 (3), 279-286, 2015
1532015
Autologous 111In‐labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United …
A Sarpatwari, D Provan, S Erqou, R Sobnack, FW David Tai, AC Newland
British journal of haematology 151 (5), 477-487, 2010
902010
The opioid epidemic: fixing a broken pharmaceutical market
A Sarpatwari, MS Sinha, AS Kesselheim
Harv. L. & Pol'y Rev. 11, 463, 2017
882017
Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims
RJ Desai, A Sarpatwari, S Dejene, NF Khan, J Lii, JR Rogers, SK Dutcher, ...
PLoS medicine 16 (3), e1002763, 2019
812019
Progress and hurdles for follow-on biologics
A Sarpatwari, J Avorn, AS Kesselheim
New England Journal of Medicine 372 (25), 2380-2382, 2015
662015
Why are biosimilars not living up to their promise in the US?
MZ Zhai, A Sarpatwari, AS Kesselheim
AMA journal of ethics 21 (8), 668-678, 2019
612019
Expressing findings from meta‐analyses of continuous outcomes in terms of risks
J Anzures‐Cabrera, A Sarpatwari, JPT Higgins
Statistics in medicine 30 (25), 2967-2985, 2011
602011
The US biosimilar market: stunted growth and possible reforms
A Sarpatwari, R Barenie, G Curfman, JJ Darrow, AS Kesselheim
Clinical Pharmacology & Therapeutics 105 (1), 92-100, 2019
532019
Competition and price among brand-name drugs in the same class: a systematic review of the evidence
A Sarpatwari, J DiBello, M Zakarian, M Najafzadeh, AS Kesselheim
PLoS medicine 16 (7), e1002872, 2019
502019
Strategies that delay market entry of generic drugs
KN Vokinger, AS Kesselheim, J Avorn, A Sarpatwari
JAMA internal medicine 177 (11), 1665-1669, 2017
482017
Evaluating the impact of the Orphan Drug Act’s seven-year market exclusivity period
A Sarpatwari, RF Beall, A Abdurrob, M He, AS Kesselheim
Health Affairs 37 (5), 732-737, 2018
462018
Reforming the Orphan Drug Act for the 21st century
A Sarpatwari, AS Kesselheim
New England Journal of Medicine 381 (2), 106-108, 2019
412019
Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study
RJ Desai, A Sarpatwari, S Dejene, NF Khan, J Lii, JR Rogers, SK Dutcher, ...
bmj 361, 2018
362018
State initiatives to control medication costs—can transparency legislation help?
A Sarpatwari, J Avorn, AS Kesselheim
New England Journal of Medicine 374 (24), 2301-2304, 2016
362016
Value-based pricing and state reform of prescription drug costs
TJ Hwang, AS Kesselheim, A Sarpatwari
Jama 318 (7), 609-610, 2017
332017
Experience with the priority review voucher program for drug development
AS Kesselheim, LR Maggs, A Sarpatwari
Jama 314 (16), 1687-1688, 2015
332015
Variation in prescription drug prices by retail pharmacy type: a national cross-sectional study
J Luo, M Kulldorff, A Sarpatwari, A Pawar, AS Kesselheim
Annals of Internal Medicine 171 (9), 605-611, 2019
322019
The system can't perform the operation now. Try again later.
Articles 1–20